Molecular Library Established via Combination of Acquired Assets and Internal Work

August, 2024

Axelyf completed acquisition of an exciting molecular library that accelerates and enables our efforts in LNP design for RNA medicines. The integrated lipid library, which includes our lead molecule and original molecules made before the acquisition the assets of 76bio, is rich in potent delivery compounds for mRNA. The medicinal and supramolecular chemistry approach is world-class and intellectual property is newly filed, placing Axelyf in a position to pursue best-in-class LNPs for applications in biomolecular delivery. We will utilize the library for our own product candidates and partner our technology for products of other companies in the future.